Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Inclusion Criteria: * 18 years of age or greater. * Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT) * Corrected visual acuity in each eye equivalent to 20/200 or better * Able and willing to give signed informed consent and follow study instructions. Exclusion Criteria: Ophthalmic: * Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. * Intraocular pressure \>36 mmHg * Known hypersensitivity to any component of the formulation, latanoprost, or to topical anesthetics. * Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s) * Refractive surgery in study eye(s) * Ocular trauma within the six months prior to screening, or ocular surgery or laser treatment within the three months prior to screening. * Evidence of ocular infection and inflammation * Clinically significant ocular disease, which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe * Central corneal thickness greater then 600 μm * Any abnormality preventing reliable applanation tonometry of either eye Systemic: * Clinically significant abnormalities (as determined by the investigator) in laboratory tests at screening. * Clinically significant systemic disease * Participation in any investigational study within 30 days prior to screening * Changes in systemic medication * Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.